Adrian Egli1, Atul Humar2, Lukas A Widmer3, Luiz F Lisboa4, Deanna M Santer4, Thomas Mueller5, Joerg Stelling3, Aliyah Baluch6, Daire O'Shea4, Michael Houghton4, Deepali Kumar2. 1. Infection Biology Laboratory, Department of Biomedicine, University of Basel Li Ka Shing Institute of Virology, University of Alberta, Edmonton. 2. Transplant Infectious Diseases and Multi-Organ Transplant Program, University Health Network, Toronto, Ontario, Canada. 3. Department of Biosystems Science and Engineering, ETH Zurich, and Swiss Institute of Bioinformatics, Basel. 4. Li Ka Shing Institute of Virology, University of Alberta, Edmonton. 5. Division of Nephrology, University Hospital Zurich, Switzerland. 6. Division of Infectious Diseases, Moffitt Cancer Center, Tampa, Florida.
Abstract
BACKGROUND: Influenza vaccine immunogenicity is suboptimal in immunocompromised patients. However, there are limited data on the interplay of T- and B- cell responses to vaccination with simultaneous immunosuppression. METHODS: We collected peripheral blood mononuclear cells from transplant recipients before and 1 month after seasonal influenza vaccination. Before and after vaccination, H1N1-specific T- and B-cell activation were quantified with flow cytometry. We also developed a mathematical model using T- and B-cell markers and mycophenolate mofetil (MMF) dosage. RESULTS: In the 47 patients analyzed, seroconversion to H1N1 antigen was demonstrated in 34%. H1N1-specific interleukin 4 (IL-4)-producing CD4(+) T-cell frequencies increased significantly after vaccination in 53% of patients. Prevaccine expression of H1N1-induced HLA-DR and CD86 on B cells was high in patients who seroconverted. Seroconversion against H1N1 was strongly associated with HLA-DR expression on B cells, which was dependent on the increase between prevaccine and postvaccine H1N1-specific IL-4(+)CD4(+) T cells (R(2) = 0.35). High doses of MMF (≥ 2 g/d) led to lower seroconversion rates, smaller increase in H1N1-specific IL-4(+)CD4(+) T cells, and reduced HLA-DR expression on B cells. The mathematical model incorporating a MMF-inhibited positive feedback loop between H1N1-specific IL-4(+)CD4(+) T cells and HLA-DR expression on B cells captured seroconversion with high specificity. CONCLUSIONS: Seroconversion is associated with influenza-specific T-helper 2 and B-cell activation and seems to be modulated by MMF.
BACKGROUND: Influenza vaccine immunogenicity is suboptimal in immunocompromised patients. However, there are limited data on the interplay of T- and B- cell responses to vaccination with simultaneous immunosuppression. METHODS: We collected peripheral blood mononuclear cells from transplant recipients before and 1 month after seasonal influenza vaccination. Before and after vaccination, H1N1-specific T- and B-cell activation were quantified with flow cytometry. We also developed a mathematical model using T- and B-cell markers and mycophenolate mofetil (MMF) dosage. RESULTS: In the 47 patients analyzed, seroconversion to H1N1 antigen was demonstrated in 34%. H1N1-specific interleukin 4 (IL-4)-producing CD4(+) T-cell frequencies increased significantly after vaccination in 53% of patients. Prevaccine expression of H1N1-induced HLA-DR and CD86 on B cells was high in patients who seroconverted. Seroconversion against H1N1 was strongly associated with HLA-DR expression on B cells, which was dependent on the increase between prevaccine and postvaccine H1N1-specific IL-4(+)CD4(+) T cells (R(2) = 0.35). High doses of MMF (≥ 2 g/d) led to lower seroconversion rates, smaller increase in H1N1-specific IL-4(+)CD4(+) T cells, and reduced HLA-DR expression on B cells. The mathematical model incorporating a MMF-inhibited positive feedback loop between H1N1-specific IL-4(+)CD4(+) T cells and HLA-DR expression on B cells captured seroconversion with high specificity. CONCLUSIONS: Seroconversion is associated with influenza-specific T-helper 2 and B-cell activation and seems to be modulated by MMF.
Authors: Annika Luukkainen; Kia Joo Puan; Nurhashikin Yusof; Bernett Lee; Kai Sen Tan; Jing Liu; Yan Yan; Sanna Toppila-Salmi; Risto Renkonen; Vincent T Chow; Olaf Rotzschke; De Yun Wang Journal: Front Immunol Date: 2018-11-08 Impact factor: 7.561
Authors: Max Schuller; Verena Pfeifer; Alexander H Kirsch; Konstantin A Klötzer; Agnes A Mooslechner; Alexander R Rosenkranz; Philipp Stiegler; Peter Schemmer; Harald Sourij; Philipp Eller; Barbara Prietl; Kathrin Eller Journal: Front Med (Lausanne) Date: 2022-02-02
Authors: Maria Magicova; Ivan Zahradka; Martina Fialova; Tomas Neskudla; Jiri Gurka; Istvan Modos; Michal Hojny; Petr Raska; Petr Smejkal; Ilja Striz; Ondrej Viklicky Journal: Transplantation Date: 2022-04-01 Impact factor: 4.939
Authors: Claudia Spies; Alawi Luetz; Gunnar Lachmann; Markus Renius; Clarissa von Haefen; Klaus-Dieter Wernecke; Marcus Bahra; Alexander Schiemann; Marco Paupers; Christian Meisel Journal: PLoS One Date: 2015-12-07 Impact factor: 3.240
Authors: Jeffrey R Curtis; Sindhu R Johnson; Donald D Anthony; Reuben J Arasaratnam; Lindsey R Baden; Anne R Bass; Cassandra Calabrese; Ellen M Gravallese; Rafael Harpaz; Andrew Kroger; Rebecca E Sadun; Amy S Turner; Eleanor Anderson Williams; Ted R Mikuls Journal: Arthritis Rheumatol Date: 2021-08-04 Impact factor: 15.483
Authors: Jeffrey R Curtis; Sindhu R Johnson; Donald D Anthony; Reuben J Arasaratnam; Lindsey R Baden; Anne R Bass; Cassandra Calabrese; Ellen M Gravallese; Rafael Harpaz; Andrew Kroger; Rebecca E Sadun; Amy S Turner; Eleanor Anderson Williams; Ted R Mikuls Journal: Arthritis Rheumatol Date: 2021-06-15 Impact factor: 15.483